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AbstrACt
Introduction Hepatocyte nuclear factor 1α (HNF1A)-
diabetes is the most common monogenetic subtype of 
diabetes. Strict glycaemic control is crucial for a good 
prognosis for patients with HNF1A-diabetes. Sulfonylurea 
(SU) is used as a first-line therapy in HNF1A-diabetes. 
However, SU therapy may be problematic as it confers a 
high risk of hypoglycaemia. We hypothesise that low dose 
of SU in combination with a dipeptidyl peptidase 4 inhibitor 
provides a safer and more efficacious treatment in patients 
with HNF1A-diabetes compared with SU as monotherapy.
Methods and analysis In a randomised, double-
blinded, crossover study, patients with HNF1A-diabetes 
will randomly be assigned to 16 weeks of treatment 
with glimepiride+linagliptin, 4 weeks of washout and 
16 weeks of treatment with glimepiride+placebo (or 
vice versa). Treatment will be evaluated with continuous 
glucose monitoring and combined meal and bicycle tests 
conducted at baseline and at the end of each of the two 
treatment periods. The primary end point is the absolute 
difference in the mean amplitude of glycaemic excursions 
between the two treatments (glimepiride+linagliptin vs 
glimepiride+placebo) at the end of each treatment period.
Ethics and dissemination The study protocol is 
approved by the Danish Medicines Agency, The Scientific-
Ethical Committee of the Capital Region of Denmark (H-
17014518) and the Danish Data Protection Agency. The 
trial will be carried out and monitored in compliance with 
Good Clinical Practice guidelines and in accordance with 
the latest version of the Declaration of Helsinki. Positive, 
negative and inconclusive results will be published at 
scientific conferences and as one or more scientific 
manuscripts in peer-reviewed journals with authorship in 
accordance with the International Committee of Medical 
Journal Editors’ recommendations.
trial registration number 2017-000204-15.
IntroduCtIon
Diabetes is a global health challenge affecting 
>400 million patients worldwide.1 A minimum 
of 1% of all cases of diabetes is due to 
heritable monogenetic subtypes of diabetes 
collectively named maturity-onset diabetes of 
the young (MODY).2 The majority of patients 
diagnosed with MODY have a mutation in the 
hepatocyte nuclear factor 1α (HNF1A) gene, 
a subtype of MODY termed MODY type 3 
or HNF1A-diabetes.3 4 The MODY diagnosis 
should be considered when an individual 
displays: (1) hyperglycaemia, (2) autosomal 
dominant inheritance of diabetes (diabetes 
in at least two consecutive generations), (3) 
early onset of diabetes (at least one family 
member with onset before 25 years of age), 
(4) measurable C-peptide levels in plasma 
3 years after diagnosis and (5) lack of auto-
antibodies against pancreatic islet cells.5 
The risk of microvascular complications 
(neuropathy, nephropathy and retinopathy) 
strengths and limitations of this study
 ► This study is the first randomised, double-blinded, 
placebo-controlled, crossover trial, which evalu-
ate combination therapy of glimepiride+linagliptin 
in patients with hepatocyte nuclear factor 1α 
(HNF1A)-diabetes.
 ► Treatment will be assessed by continuous glucose 
monitoring, which provides a comprehensive over-
view of glucose fluctuations in addition to haemo-
globin A1c and patient-reported outcomes including 
episodes of hypoglycaemia.
 ► Treatment effects on endocrine pancreas function 
and hypoglycaemic response will be thoroughly 
evaluated during a combined meal and bicycle test.
 ► Due to the relatively small sample size, secondary 
outcome measures might not be generalisable to all 
patients with HNF1A-diabetes.
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and macrovascular complications (eg, stroke, myocardial 
infarction and peripheral artery disease) in HNF1A-di-
abetes is similarly high to that of patients with type 2 
diabetes.6 Thus, strict glycaemic control combined with 
reduction of other cardiovascular risk factors and proper 
treatment of complications are crucial for a good prog-
nosis.6 7 
A key characteristic of HNF1A-diabetes is a reduced 
glucose-induced insulin response.8 In the insulin-se-
creting beta cells, the turnover of glucose (glycolysis) is 
impaired. This results in reduced intracellular levels of 
adenosine triphosphate (ATP). Decreased ATP levels 
impede ATP-dependent potassium channel (KATP-
channel) essential to exocytosis of insulin. Sulfonylurea 
(SU) binds to SU receptor 1 (SUR1), a subunit of the 
KATP-channel, hereby closing the channel. This causes 
membrane depolarisation leading to opening of the volt-
age-gated calcium (Ca2+) channel and increasing intracel-
lular Ca2+ concentration, which in turn causes docking of 
secretory vacuoles and exocytosis of insulin (ie, insulin 
secretion).9 10 Due to a high sensitivity to SUs combined 
with normal or even increased insulin sensitivity, this 
treatment is highly effective with respect to lowering of 
plasma glucose.
Thus, SU treatment is currently the recommended first-
line therapy in patients with HNF1A-diabetes and is in 
general well-tolerated and considered safe.11 12 However, 
due to the glucose-independent action of SUs, they confer 
a risk of hypoglycaemia even when relatively low doses are 
used.12 13 In 2006, Tuomi et al14 demonstrated that 40% 
of their patients with HNF1A-diabetes developed hypo-
glycaemia during physical exercise (ie, light cycling for 
30 min 2 hours after meal ingestion) when treated with 
SU (glibenclamide). One patient experienced prolonged 
hypoglycaemia for 12 hours. In a clinical setting, some 
patients with HNF1A-diabetes have recurrent episodes 
of hypoglycaemia on SU treatment. In these patients, 
a reduction of SU dosing may protect against hypogly-
caemia; however, this may be at the expense of good 
glycaemic control. Therefore, patients with HNF1A-di-
abetes with recurrent hypoglycaemia on SU treatment 
and unsatisfactory haemoglobin A1c (HbA1c) levels may 
benefit of a more effective treatment with a lower risk of 
hypoglycaemia.
In healthy individuals, the incretin hormones 
glucose-dependent insulinotropic peptide (GIP) and 
glucagon-like peptide-1 (GLP-1) are important regula-
tors of plasma glucose due to their effects on insulin and 
glucagon secretion. GIP and GLP-1 are secreted from 
enteroendocrine cells in the intestinal epithelium.15 The 
major secretory stimulus is the presence of nutrients in 
the gut lumen.16 GLP-1 exerts potent insulinotropic and 
glucagonostatic effects in a glucose-dependent fashion; 
that is, the insulin-stimulating and glucagon-suppressive 
effects only are active during elevated plasma glucose 
levels (>4–5 mmol/L). GIP displays a similar glucose-de-
pendent insulinotropic effect as GLP-1 in healthy adults, 
but it does not exert any glucagon-suppressive effect; in 
fact, GIP has been shown to stimulate glucagon secretion 
during euglycaemia or hypoglycaemia.17 This glucose-de-
pendency makes the incretin hormones essential as 
‘glucose-stabilisers’ that decrease high glucose levels 
and elevate glucose levels during hypoglycaemia.18 In 
HNF1A-diabetes incretin hormones are secreted in a 
normal fashion, but the insulinotropic effect of GIP 
and GLP-1, respectively, is diminished.19 Both incretin 
hormones are degraded rapidly by the ubiquitous 
enzyme dipeptidyl peptidase 4 (DPP-4). Patients with 
HNF1A-diabetes display increased DPP-4 activity during 
fasting, but the significance of this finding is unknown.19 
Incretin-based drugs are increasingly being used for the 
treatment of patients with type 2 diabetes: (1) DPP-4 
inhibitors prevent breakdown of endogenously secreted 
incretin hormones and (2) injectable DPP-4 resistant 
GLP-1 receptor agonists (GLP-1RA) result in supraphys-
iological levels of circulating GLP-1RA.20 21 In a recent 
randomised controlled trial, we compared treatment with 
SU and GLP-1RA in HNF1A-diabetes and demonstrated 
significant reductions in fasting plasma glucose and post-
prandial glucose excursions in patients with HNF1A-dia-
betes with both treatments.12 The glucose-lowering effect 
was greater with SU, but at the expense of a markedly 
higher risk of hypoglycaemia.
HypotHEsIs And AIM
We hypothesise that a low dose of glimepiride (a SU 
compound) in combination with linagliptin (a DPP-4 
inhibitor) will provide an efficacious and safe treatment 
with a better glycaemic control and lower risk of hypogly-
caemia compared with glimepiride as monotherapy. The 
rationale for combination therapy is: (1) DPP-4 inhibitors 
will display a glucose-dependent insulinotropic effect elic-
ited by increased concentrations of active GIP and GLP-1; 
(2) DPP-4 inhibitors may protect against hypoglycaemia 
due to the added effects by GIP on glucagon secre-
tion; (3) the small dose of SU will compensate for the 
decreased ATP levels and the malfunction of KATP in the 
insulin-secreting beta cells; (4) SU given in a low dose (in 
combination with a DPP-4 inhibitor) will protect against 
hypoglycaemia.
study objECtIvE
The objective of this study is to investigate the efficacy 
and safety of combination therapy with glimepiride and 
linagliptin compared with glimepiride monotherapy in 
patients with HNF1A-diabetes. The primary end point is 
the difference in glycaemic variability defined as mean 
amplitude of glycaemic excursions (MAGE) between 
the two treatment arms at end of treatment. MAGE has 
been chosen as most patients with HNF1A-diabetes have 
only mildly deranged fasting plasma glucose values and 
marked postprandial hyperglycaemia. An improvement 
in MAGE corresponds with an improvement of postpran-
dial hyperglycaemia. Secondary end points consist of 
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several parameters evaluating glycaemic variability, long-
term glycaemic control and hypoglycaemia.
MEtHods And AnAlysIs
study design
This trial is a single-centre, randomised, double-blinded, 
crossover study in patients with HNF1A-diabetes (figure 1). 
The study is intended to show superiority of glimepiri-
de+linagliptin in regard to the primary end point.
study participants
A total of 20 patients with HNF1A-diabetes will be enrolled. 
Patients will be recruited from the diabetes outpatient 
clinics at Gentofte Hospital and Steno Diabetes Center 
Copenhagen, Denmark or by letter to patients registered 
in a database at Steno Diabetes Center Copenhagen. All 
trial activities will be executed at Clinical Metabolic Phys-
iology, Steno Diabetes Center Copenhagen, Gentofte 
Hospital, Hellerup, Denmark.
The total number of participants in the following 
categories will be recorded: invited, excluded before 
screening (including reasons for exclusion), declined to 
participate, not reached, screened, excluded at screening, 
randomised, completed intervention period, withdrew/
dropped out during the study period (including reason 
for withdrawal/dropping out), lost to follow-up and 
Figure 1 Trial design. Patients with hepatocyte nuclear factor 1α-diabetes will be randomly assigned to one of two double-
blinded treatment sequences: (1) 16 weeks of treatment with glimepiride+linagliptin, 4 weeks of washout and 16 weeks of 
treatment with glimepiride+placebo (blue boxes); and (2) 16 weeks of treatment with glimepiride+placebo, 4 weeks of washout 
and 16 weeks of treatment with glimepiride+linagliptin (green boxes). Evaluation of the glycaemic variability will be assessed 
by continuous glucose monitoring (CGM) and meal and bicycle test in weeks 0, 16 and 36. For other investigations during the 
study, see text for more details.
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analysed. Eligible participants will receive written and 
oral information about study. Sufficient time for reflec-
tion will be given before written informed consent is 
obtained as according to The International Conference 
on Harmonisation of Technical Requirements for Regis-
tration of Pharmaceuticals for Human Use (ICH) Good 
Clinical Practice (GCP) guidelines.
Eligibility of participants
Inclusion criteria
 ► Patients with HNF1A-diabetes caused by heterozygous 
mutation in HNF1A confirmed by Sanger sequencing 
of the gene.
 ► Monotherapy with diet or a stable dose of glimepiride 
of (≥0.5 mg/day) during 4 weeks.
 ► Patients on glimepiride treatment: HbA1c≥6.5% 
(HbA1c≥48 mmol/mol).
 ► Patients receiving no glucose-lowering agents: 
HbA1c≥7.0% (HbA1c≥53 mmol/mol).
 ► Age≥18 years of age.
 ► Capability to perform a 30 min light bicycle test at a 
heart rate of 100–120 beats per min.
 ► Fertile females must use adequate contraceptive 
method (intrauterine contraceptive devices or 
hormonal contraception).
 ► Informed consent.
Exclusion criteria
 ► Use of glucose-lowering drugs other than glimepiride.
 ► Uraemia, end-stage renal disease or estimated glomer-
ular filtration rate<30 mL/min/1.73 m2 and/or 
albuminuria.
 ► Liver disease and/or serum alanine aminotransferase 
(ALT) and/or serum aspartate aminotransferase 
(AST)>2× upper normal serum levels.
 ► Anaemia (males blood haemoglobin <8.0 mmol/L 
and females <7.0 mmol/L).
 ► History of acute and/or chronic pancreatitis.
 ► Pregnancy or breast feeding.
 ► Inability to complete the study.
 ► Known allergic reaction to study medication.
 ► Intention to become pregnant.
Intervention
Participants will be randomly assigned to one of two treat-
ment sequences: (1) 16 weeks of treatment with glime-
piride+linagliptin, 4 weeks of washout and 16 weeks of 
treatment with glimepiride+placebo or (2) 16 weeks of 
treatment with glimepiride+placebo, 4 weeks of washout 
and 16 weeks of treatment with glimepiride+linagliptin. 
Patients treated with glimepiride at screening will 
continue on the same dosage after randomisation. Treat-
ment-naïve patients will start on 0.5 mg glimepiride after 
randomisation. Each treatment period is divided into a 
drug-titration period (weeks 1–4) and a maintenance 
period (weeks 5–16). After initiation of linagliptin/
placebo patients will continue on the initial dose of glime-
piride at screening for 1 week. Patients are instructed to 
measure fasting plasma glucose values daily. After the 
first week of linagliptin/placebo, the glimepiride dose 
will be adjusted for the first time. Target fasting plasma 
glucose (average during at least 5 days) is between 4.5 
and 6.0 mmol/L (both inclusive) without episodes of 
symptomatic or biochemical hypoglycaemia (plasma 
glucose≤3.9 mmol/L). In case of no hypoglycaemia and 
an average fasting plasma glucose>6 mmol/L, the glime-
piride dose will be increased with 0.5 mg. In case of hypo-
glycaemia or average fasting plasma glucose <4.5 mmol/L, 
the dose of glimepiride will be decreased by 0.5 mg. In the 
remaining titration period, the glimepiride dose will be 
uptitrated or downtitrated once-weekly in the same treat-
to-target manner with a maximum daily dose of 6 mg in 
both groups. A total daily dose of glimepiride≥1 mg will be 
divided and administered as two daily doses: one dose in 
the morning and one dose in the evening. If target fasting 
plasma glucose is not achieved during the drug-titration 
period, the dose of glimepiride will be adjusted after week 
4 at the investigators discretion. In case of hypoglycaemia 
outside of the drug-titration period, glimepiride dose 
will be down-titrated 0.5 mg. Once-daily linagliptin 5 mg 
or placebo will be initiated at each treatment period and 
the dose kept stable throughout the experiment. After 
the first treatment period, the dose of glimepiride at 
randomisation will immediately be reintroduced for all 
patients and followed by a 4-week ‘linagliptin/placebo’ 
washout period. Participants will be encouraged not to 
change their lifestyle (ie, diet, exercise and smoking 
status) during the trial. There will be no restriction to 
concomitant non-antidiabetic medications. Trial medi-
cine will comply with Good Manufacturing Practice. Drug 
accountability will be performed at all clinical visits to 
document degree of compliance.
outcomes
Primary outcome measurements
The primary end point is the absolute difference in MAGE 
between the two treatments (glimepiride+linagliptin vs 
glimepiride+placebo) at the end of each treatment period 
calculated from 6 days (144 hours) of continuous glucose 
monitoring (CGM).
Secondary outcome measurements
Secondary end points include differences between the 
two treatments (glimepiride+linagliptin vs glimepiride+-
placebo) in:
 ► Other parameters of glycaemic variability including 
low blood glucose index (LBGI), SD of mean glucose, 
time spent in hypoglycaemia and time spent in hyper-
glycaemia calculated from 6 days of CGM at the end of 
each treatment period.
 ► Difference between baseline and end of treatment in 
parameters of glycaemic variability including MAGE, 
LBGI, SD of mean glucose, time spent in hypogly-
caemia, time spent in hyperglycaemia from 6 days of 
CGM.
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 ► The absolute glycaemic excursion during meal and 
bicycle test.
 ► Change in pancreatic endocrine function during meal 
and bicycle tests (insulin, C-peptide and glucagon).
 ► Change in counter-regulatory responses to hypo-
glycaemia during meal and bicycle tests (growth 
hormone (GH), cortisol and norepinephrine).
 ► Number and severity of hypoglycaemic events during 
meal and bicycle tests.
 ► Number and severity of hypoglycaemic events during 
treatment periods.
 ► Fasting plasma glucose at the end of each treatment 
period.
 ► HbA1c at end of trial.
 ► Fructosamine at end of trial.
 ► Changes in bodyweight from baseline.
 ► Changes in cardiovascular biomarkers in urine.
 ► Changes in quality of life from baseline evaluated with 
Short Form-36.
 ► Dose of glimepiride at the end of each treatment 
period.
 ► Differences between treatments in the proportion of 
patients achieving HbA1c<6.5% (HbA1c<48 mmol/
mol) (or a decrease in HbA1c>5 mmol/mol compared 
with baseline) and have no episodes of hypoglycaemia 
during the study.
The outcome parameters are defined in box 1.
participant timeline
Participant timeline is illustrated in table 1. Study treat-
ment will be evaluated with clinical visits and blood 
samplings, telephone calls, CGM and meal and bicycle 
test. The full study period constitutes of 36 weeks (one 
washout period of 4 weeks and two treatment periods 
of 16 weeks), preceded by a pretreatment evaluation 
(screening) approximately 14 days before randomisation.
screening
Participants will be screened according to inclusion and 
exclusion criteria. Demographics and medical history will 
be obtained, including recording of current medication 
and previous tests verifying the diagnosis of HNF1A-dia-
betes. Vital signs (blood pressure and pulse), height and 
weight, waist and hip circumference will be measured 
and a physical examination will be performed. Screening 
blood samples will be taken including haemoglobin, 
creatinine, electrolytes (Na+, K+), C reactive protein 
(CRP), thyroid-stimulating hormone (TSH), ALT, AST, 
bilirubin, alkaline phosphatase, albumin, plasma glucose, 
HbA1c, urine examined for albumin:creatinine ratio and 
cardiovascular biomarkers. Fertile women will undergo 
a pregnancy test (urine sample). If the potential partici-
pant meets all inclusion criteria and none of the exclusion 
criteria, an appointment for the following visits (randomi-
sation) will be set up. For screening failures (patients who 
were screened, but not randomised), a screening failure 
form will be completed.
ContInuous gluCosE MonItorIng
Blinded CGM measurements will be conducted over 
6 days three times during the trial at baseline and after 
each treatment period (weeks 0, 16 and 36). Urine 
samples will be collected daily during CGM.
telephone contacts
During the 36 weeks, a total of six telephone calls will be 
conducted. At these contacts, the glimepiride treatment 
box 1 definition of outcomes
 ► MAGE is a measure of glycaemic variability. It quantifies the mean 
amplitude of all glycaemic excursions that exceed 1 SD of the plas-
ma glucose within the last 24 hours. High MAGE values are strongly 
associated with hyperglycaemia.
 ► LBGI is a measure of glycaemic variability. It describes the frequency 
and extent of hypoglycaemia. High values of LBGI are correlated 
with high risk of severe hypoglycaemia.
 ► Other measures of glycaemic variability will include SD of mean glu-
cose, time spent in hypoglycaemia and time spent in hyperglycaemia.
 ► The absolute glycaemic excursion evaluated as the absolute differ-
ence from the highest and lowest plasma glucose   measurement 
during meal and bicycle test.
 ► Pancreatic endocrine function evaluated as AUC for plasma insulin, 
C-peptide and glucagon during meal and bicycle test.
 ► Counter-regulatory responses to hypoglycaemia evaluated as AUC 
for plasma GH, cortisol and norepinephrine during meal and bicycle 
test.
 ► Number and severity of hypoglycaemic events for each treatment 
period will be reported by patients in diaries. Hypoglycaemic events 
will be described according to the American Diabetes Association’s 
recommendations.
 ► Number and severity of hypoglycaemic events during meal and bi-
cycle test will be measured as defined in the bullet point above.
 ► Fasting plasma glucose defined as plasma glucose measurement 
taken after at least an 10 hours fast.
 ► HbA1c is an indicator for time-averaged long-term plasma glucose 
levels and thus glycaemic control over approximately 90–120 days.
 ► Fructosamine is an indicator for time-averaged plasma glucose lev-
els over 2–3 weeks. It reflects the total amount of glycated plasma 
proteins.
 ► Bodyweight will be measured before and after treatment in both 
arms at the day of meal and bicycle test.
 ► Changes in the cardiovascular biomarker 8-oxoGuo: 8-oxoGuo is 
a urinary marker of oxidative stress. 8-oxoGuo is produced when 
free radicals oxidise ribonucleic acids. Increased urinary excretion 
of 8-oxoGuo has been associated with increased mortality in newly 
diagnosed type 2 diabetes patients and after 6 years.
 ► Changes in quality of lifeevaluated with SF-36: SF-36 is a validated 
questionnaire for health-related quality of life measurement in type 
2 diabetes. A decrease in the score in SF-36 have been linked to 
increased risk of hospitalisation and mortality.
 ► Dose of glimepiride at the end of each treatment period as total daily 
dose of glimepiride.
 ► Differences between treatments in the proportion of patients 
achieving HbA1c<48 mmol/mol (or a decrease in HbA1c>5 mmol/
mol compared with baseline) and have no episodes of hypoglycae-
mia during the study.
8-oxoGuo, 8-oxo-7,8-dihydroguanosiene; AUC, area under the curve; GH, 
growth hormone; HbA1c, haemoglobin A1c; LBGI, low blood glucose index; 
MAGE, mean amplitude of glycaemic excursions; SF-36, Short Form 36.
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will be titrated as described previously according to 
patients’ diaries, reported hypoglycaemic episodes and 
adverse events (AE). Compliance will be noted. Patients 
will be informed to continue on 5 mg of linagliptin/
placebo forward. The telephone contacts will be done in 
the drug-titration periods (weeks 1, 2, 3, 21, 22 and 23).
Clinical visits and blood sampling
Patients will meet for eight clinical visits. Compliance and 
AEs will be noted. At clinical visits dispensing of trial drugs 
will be done. Blood samples will be performed during 
clinical visits and at the end of study. The following anal-
ysis will be performed: haemoglobin, vitamin b12, creat-
inine, electrolytes (Na+, K+), leucocytes, thrombocytes, 
CRP, C-peptide, cholesterols, triglycerides, TSH, CRP, 
bilirubin, ALT, AST, alkaline phosphatase, albumin, coag-
ulation factors, plasma glucose, HbA1c and fructosamine. 
Visits are scheduled for weeks 4, 8, 12, 16, 24, 28, 32 and 
36.
Meal and bicycle test
Three meal and bicycle tests (figure 2) will be performed 
at baseline and in the end of each of the two treatment 
periods (weeks 0, 16 and 36). Patients will be subjected to a 
standard 4-hour liquid meal test and a concurrent 30 min 
bicycle test. The patients will meet in a fasting (10 hours) 
state. Patients will continue their therapy according to 
trial protocol and thus take glimepiride tablets as normal 
the evening before, and glimepiride and linagliptin/
placebo tablets at the clinic 1 hour prior to the ingestion 
of the meal (time −60 min). Patients will ingest a stan-
dard liquid meal (525 kcal: 65 g carbohydrate, 20 g fat, 
21 g protein) added 1.5 g of paracetamol at time 0 min. 
From 60 to 90 min, a 30 min bicycle test will be performed 
(initially 50–60 rotations per minute, with adjustment of 
bicycle resistance every 5 min until achieving a heart rate 
of 90–110 beats per min). Symptoms of hypoglycaemia 
will be monitored and plasma glucose measured on 
Table 1 Participant timeline
Time (weeks) >−1 0 1 2 3 4 8 12 16 17–20 21 22 23 24 28 32 36
Screening x
Randomisation x
Drug-titration period x x x x x x x x
Clinical visit+blood samples x x x x x x x x x
Telephone call x x x x x x
Continuous glucose monitoring x x x
Meal and bicycle test x x x
Washout x
Colours: grey: screening, randomisation and washout period; blue: treatment period 1: glimepiride+linagliptin or glimepiride+placebo; orange: 
treatment period 2: the opposite treatment of period 1. 
Figure 2 Meal and bicycle test. Participants arrive fasting. Study medication is taken at time −60 min. At time 0 min a mixed 
liquid meal (525 kcal) added 1.5 g of paracetamol is served. From 60 to 90 min, a light bicycle test is performed (target heart rate 
90–110 beats per min). Blood samples are taken for the analysis of plasma glucose, insulin, C-peptide, glucagon, incretins and 
counter-regulatory hormones. Patients will be monitored for any symptoms of hypoglycaemia. FPG, fasting plasma glucose.
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prespecified time points and in the event of symptoms 
of hypoglycaemia. Other AEs and compliance will also be 
noted. During the meal test, blood samples will be drawn 
at prespecified time points for measurement of plasma 
glucose, insulin, C-peptide, glucagon, GIP, GLP-1, parac-
etamol and counter-regulatory hormones (GH, cortisol, 
norepinephrine).
sample size
The study is a superiority study which will estimate the 
effect of two different treatments with the hypothesis that 
the effect of treatment with glimepiride+linagliptin versus 
glimepiride+placebo will display a significant decrease in 
MAGE.
For power calculation on our primary end point, the 
following equation has been used as recommended by 
Jones and Kenward22:
N = (Z
α
+Zβ)
2×SD2/MIREDIF2
 ► Z
α
 is a table value according to a two-sided standard 
normal distribution;
 ► Zβ is a table value according to a one-sided standard 
normal distribution;
 ► SD is the standard deviation;
 ► MIREDIF is the minimum relevant difference.
The power of our study (1−β) will be set at 0.8, and the 
risk of accepting a false hypothesis is 0.20 (β=0.20) with 
a significance level at 0.05 (α=0.05). Thus, Z
α
=1.96 and 
Zβ=0.84. We have defined a minimal relevant difference 
(MIREDIF) of 2 mmol/L (36 mg/dL) in MAGE between 
the two groups. Power calculation in the current trial has 
been based on the SD (SD=50) in MAGE presented by 
Saisho et al.23
Number of participants needed:
N=(1.96+0.84)2×502/362=15.1≈16
In order to allow drop-outs, a total of 20 patients with 
HNF1A-diabetes will be randomised. With the chosen size 
sample a risk of type 2 error exists, thus missing an effect 
of glimepiride+linagliptin versus glimepiride placebo. 
However, we consider only an effect that can be found 
within a sample size of 20 patients to be clinically relevant.
Assignment of interventions
Patients will be randomised in 1:1 allocation using a 
computer-generated random list of numbers. The list 
of random numbers will be made by an employee who 
is otherwise uninvolved in the study. The allocation will 
not be known to the investigators or patients during the 
study. Everyone involved in the trial will be blinded until 
data are fully analysed. Code break of a participant’s 
trial medicine will occur during the trial only in case of 
exceptional circumstances when knowledge of treatment 
is absolutely necessary. Only the sponsor-investigator and 
an employee who is otherwise uninvolved in the study will 
be able to perform a code break.
data collection, analysis and management
All data will be collected in electronic case report forms 
in Research Electronic Data Capture (REDCap) hosted 
at the Capital Region of Denmark. REDCap is a secure, 
web-based application designed to support data capture 
for research studies, providing: (1) an intuitive inter-
face for validated data entry; (2) audit trails for tracking 
data manipulation and export procedures; (3) auto-
mated export procedures for seamless data downloads 
to common statistical packages and (4) procedures for 
importing data from external sources.24 The case report 
forms will only be available for investigators and monitors 
according to ICH-GCP guidelines.25 The database will 
be locked database after last participant’s end-of-study 
visit. Only investigators will have access to the final data 
set. To ensure adherence to protocol, a designated trial 
project coordinator will be responsible for reminding 
patients of dates for visits and clinical tests. Additionally, 
drug accountability will be performed to ensure compli-
ance. CGM monitors used will be the iPro2 CGM from 
Medtronic, Northridge, California, USA, which has 
been validated elsewhere.26 To ensure data collection, 
only CGM-trained investigators will assemble and disas-
semble the CGM monitor at the study site. Investigators 
will receive training by Medtronic representatives before 
commencement of the trial. All data are stored electroni-
cally by the CGM device and uploaded to a server hosted 
by Medtronic. If participants have any problems with their 
CGM monitor, an investigator will always be accessible by 
phone and provide guidance. If a problem with the CGM 
monitor persists, additional clinical visits will be arranged 
to ensure data collection.
Blood and urine samples from screening visits, clin-
ical visits and meal and bike tests will be analysed in the 
Department of Biochemistry at Gentofte Hospital or 
collaborators according to predefined local standards. 
Additional blood and urine will be stored in the research 
biobank in case of the need of re-analysis.
data monitoring
The trial will be monitored by the GCP unit, Bispeb-
jerg Hospital, University of Copenhagen, Copenhagen, 
Denmark. The GCP unit and the Danish Medicines Agency 
will be able to conduct an audit of the trial independent 
of sponsor-investigator and investigators. There will be 
no data monitoring committee due to (1) the relatively 
short duration of the study, and because (2) the drugs 
used in this trial are approved and considered safe. At 
all telephone contacts and clinical visits, patients’ adverse 
events, if any, will be noted in the case report forms. Addi-
tionally, patients will be encouraged to contact the inves-
tigators in case of any AE. Participants will be thoroughly 
informed of potential side effects when participating in 
this trial. All AEs will be reported to the Danish Medi-
cines Agency and the Scientific-Ethical Committee of 
the Capital Region of Denmark at the end of trial. Spon-
sor-investigator shall be further responsible for reporting 
of any serious adverse event (SAE), serious adverse reac-
tion (SAR) and suspected unexpected serious adverse 
reaction (SUSAR), which occur during the conduct 
of the study to the Scientific-Ethical Committee of the 
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Capital Region of Denmark once yearly in accordance 
with the applicable laws and regulations. Sponsor-inves-
tigator will delegate the responsibility for the expedited 
regulatory reporting of SAE, SAR and SUSAR to Boeh-
ringer Ingelheim. The sponsor-investigator will report 
every SAE, SAR and SUSAR immediately to Boehringer 
Ingelheim within 24 hours. Boehringer Ingelheim will be 
responsible to report SAE, SAR and SUSAR to the Danish 
Medical Agency in accordance with the applicable laws 
and regulations.
statistical analysis
All analyses will be performed on an intent-to-treat sample 
of subjects who were randomised and received at least 
one dose of medication or placebo. Continuous data will 
be summarised by descriptive statistics with the number 
of observations (n), mean, SD, minimum, median and 
maximum. Categorical data will be summarised in 
frequency tables using count and percentages. AUC 
will be calculated using the trapezoidal rule. Compari-
sons between treatment outcomes will be performed in 
linear mixed models for continuous data. Comparisons 
of binary or ordinal data will be performed in generalised 
linear models for binary or ordinal data. Missing data will 
implicitly be imputed by performing likelihood infer-
ence in the linear mixed models for continuous data. 
Interaction between treatment and treatment period will 
be performed in linear mixed models to test for poten-
tial carryover effect. Outcomes that are not normally 
distributed will be transformed for the analysis in linear 
mixed models. Not normally distributed outcomes will be 
presented as median and ranges. All tests will be carried 
out at a significance level of 5%. AEs will be summarised 
qualitatively.
strengths and limitations
The strength of this study is the randomised, placebo-con-
trolled, double-blinded trial design. The crossover design 
means the patients will be their own control. Glucose-low-
ering treatment will be evaluated regarding all glucose 
parameters: glucose variability, long-term glycaemic 
control (HbA1c) and by the amount of hypoglycaemic 
events. The duration of each treatment period (16 weeks) 
will provide time to asses both the efficacy of treatments 
and risk of hypoglycaemia. The crossover design has the 
advantage that it reduces the risk of confounding covari-
ates by unbalanced randomisation. However, the disad-
vantage of a crossover study is if participants change 
during the study (eg, gain weight) or if there is a carry-
over effect from one treatment period to another. Given 
the 4-week washout period the risk of a carryover effect 
is minimal. The major limitation of this study is the small 
sample size and rather short duration of the study. Thus, 
the results of this study might not be generalisable to 
all patients with HNF1A-diabetes. Another limitation is 
that participants at randomisation will receive different 
baseline doses of glimepiride. This may cause different 
levels of saturation of the SUR1 and thereby potentially 
interindividual differences to an increment of the glime-
piride dose. Third, a limitation of this study is that it might 
be hard to recruit patients given the criteria for partici-
pation and the relatively few diagnosed with HNF1A-dia-
betes in Denmark.
patient and public involvement
This study is designed to address the well-known dysreg-
ulation and risk of hypoglycaemia in patients with 
HNF1A-diabetes treated with SU as monotherapy. We 
expect the study to provide knowledge about the combi-
nation therapy with DPP-4 inhibitors and SU, which 
from a mode of action point of view make a lot of sense. 
Currently, neither patients nor patient advisers have been 
involved in the design, recruitment and conduct of the 
study. All participants will receive a personal treatment 
evaluation and an evaluation of the whole population in 
writing after a full data analysis has been performed. The 
intervention burden will be assessed by the recording of 
all episodes of AE and/or SAE according to GCP.
EtHICs And dIssEMInAtIon
The sponsor-investigator is responsible for informing 
participants, investigators and the Danish Medicines 
Agency and The Scientific-Ethical Committee of the 
Capital Region of Denmark of any amendments to the 
protocol as per national requirements. The study will 
be conducted with informed consent from partici-
pants according to the Declaration of Helsinki. All data 
forms and blood samples will be anonymised and only 
be labelled with the patient’s initial and study number. 
Sponsor-investigator is responsible for keeping a list sepa-
rately for all randomised participants containing patient 
numbers, full names and date of birth. Patients in the 
study will be covered by insurance via the hospital. Posi-
tive, negative and inconclusive results will be published 
at scientific conferences and as one or more scientific 
manuscripts in peer-reviewed journals with authorship 
in accordance with International Committee of Medical 
Journal Editors.
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